http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008039898-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70f787562faedf306d2bdbb76c976219
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_565d23a3626bbf3eb356298484b7a738
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_89a75a9da1e97660158161a90dfa58c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_80815d996dc77a39f52ee1bfdb901d24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d2adfd663fa901d5ccdee48c6d1ba40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60da379fb33c192ef77f86a60c5ac029
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
filingDate 2007-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d18da8d27c51203a15c1b3e2874aed2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89a2f1d08e3f20618bd8da587afe7057
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea5259ad655e81e35e1d93a6b1885aa3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e44d19dd02f826d43240203a3fb7234a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da4adc50f6e5d2c73c5ecc05e0bb8a31
publicationDate 2008-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2008039898-A3
titleOfInvention Methods for the treatment of a traumatic central nervous system injury
abstract Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two- level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.
priorityDate 2006-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0230409-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006102596-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553937
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134688829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399016
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323226

Total number of triples: 30.